封面
市場調查報告書
商品編碼
2179078

人工智慧驅動的精準腫瘤平台市場預測至2034年——全球平台組件、人工智慧技術、數據模式、臨床應用、最終用戶和地區分析

AI-Driven Precision Oncology Platforms Market Forecasts to 2034 - Global Analysis By Platform Component (Software and Services), AI Technology, Data Modality, Clinical Application, End User and By Geography

出版日期: | 出版商: Stratistics Market Research Consulting | 英文 300+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據,全球人工智慧驅動的精準腫瘤學平台市場在 2026 年估計為 32 億美元,預計到 2034 年將達到 134 億美元,預測期內複合年成長率為 19.6%。

人工智慧驅動的精準腫瘤學平台利用機器學習、深度學習、自然語言處理和多模態分析技術,分析分子、臨床和影像數據,從而實現個人化癌症治療。癌症發生率的上升、基因組分析的日益普及以及對個人化治療決策需求的不斷成長,正在推動市場發展。生成式人工智慧、分子診斷和預測分析技術的進步,正在提升臨床決策支援能力。對精準醫療、腫瘤學研究和數位醫療基礎設施的持續投入,正在為醫院、癌症中心和製藥公司創造商機。

對個人化癌症治療和人工智慧驅動的臨床決策支援的需求日益成長。

對個人化癌症治療和人工智慧驅動的臨床決策支援日益成長的需求,正在推動精準腫瘤學平台的普及應用。醫療服務提供者正擴大利用基因組分析、分子診斷和人工智慧來識別可操作的生物標記,並輔助治療方案的選擇。這些平台能夠幫助臨床醫生解讀複雜的分子訊息,並評估標靶治療方案。癌症發生率的上升、精準醫療計畫的擴展以及基因組數據可用性的提高,都在推動精準腫瘤學平台的普及應用。機器學習和臨床數據整合技術的進步,也進一步促進了市場的發展。

實施成本高昂,且臨床數據整合面臨許多挑戰

高昂的實施成本和臨床數據整合的挑戰阻礙了人工智慧驅動的精準腫瘤學平台的普及應用。先進的解決方案需要複雜的運算基礎設施、安全的資料環境、專業人員以及與現有醫療資訊系統的整合。基因組資料格式、電子健康記錄和診斷流程的差異增加了互通性的難度。特定人工智慧服務的保險報銷限制以及臨床有效性的不確定性也構成了進一步的障礙。小規模的醫療機構在實施綜合平台時可能會面臨財務和技術方面的挑戰。

多模態人工智慧和整合精準腫瘤學應用的擴展

多模態人工智慧和精準腫瘤學應用的擴展帶來了巨大的成長機會。先進的平台整合了基因組圖譜、數位病理學、醫學影像和臨床記錄,從而產生全面的患者資訊。生成式人工智慧和基礎模型為改善分子層面的解讀、臨床試驗配對和治療研究提供了契機。製藥公司正日益利用人工智慧驅動的分析技術進行生物標記發現和標靶治療開發。對整合醫療數據平台和個人化腫瘤學的持續投入正在推動技術創新。

人們擔憂演算法的可靠性以及日益增加的患者資料安全風險。

對演算法可靠性的擔憂以及患者資料安全風險的增加,為人工智慧驅動的精準腫瘤學平台帶來了重大挑戰。不準確的分子分析、偏差的訓練資料集或檢驗不足的預測都可能影響臨床決策。處理敏感的基因組和患者資訊引發了網路安全和保密方面的擔憂。日益嚴格的監管審查和對可解釋人工智慧(XAI)不斷成長的要求推高了開發成本。與現有臨床決策支援系統和傳統分子分析流程的競爭,進一步加劇了商業化和應用推廣的難度。

新型冠狀病毒(COVID-19)的影響:

新冠疫情加速了醫療數位化進程,並提升了人們對遠距臨床協作和人工智慧診斷技術的興趣。在常規醫療服務中斷期間,腫瘤相關機構探索利用數位平台來支持分子腫瘤委員會、臨床數據解讀和治療方案。然而,癌症診斷的延遲、臨床試驗的中斷以及醫療預算的限制影響了這些技術的應用。隨後,對數位醫療基礎設施、精準醫療和人工智慧腫瘤工作流程的投資持續成長,推動了市場發展。

在預測期內,軟體領域預計將佔據最大的市場佔有率。

人工智慧驅動的分子層次解讀、臨床決策支援和整合腫瘤分析平台的日益普及,預計將推動軟體領域在預測期內佔據最大的市場佔有率。軟體解決方案整合基因組數據、電子健康記錄和診斷訊息,以支援個人化治療決策。精準腫瘤學計畫、雲端醫療平台和自動化生物標記分析的投資增加,正在推動其應用。機器學習、工作流程整合和可擴展臨床分析的進步,進一步促進了該領域的成長。

預計在預測期內,多模態人工智慧和基礎模型細分市場將呈現最高的複合年成長率。

在預測期內,由於對整合解讀各種腫瘤資料集的需求日益成長,多模態人工智慧和基礎建模領域預計將呈現最高的成長率。這些技術結合了基因組資訊、病理影像、放射學觀察和臨床記錄,以支持全面的癌症評估。基礎模型、生成式人工智慧和運算基礎設施的進步正在增強分析能力。對個人化治療預測、生物標記發現和腫瘤學研究投入的增加預計將加速這些技術的應用。

市佔率最大的地區:

在預測期內,北美預計將佔據最大市場佔有率,這主要得益於其先進的醫療基礎設施、對人工智慧的大量投資以及廣泛的精準腫瘤學活動。美國正透過生物技術公司、癌症研究中心和醫療機構推動區域發展,這些機構正在採用人工智慧驅動的分子分析平台。基因組檢測的日益普及、完善的臨床試驗網路以及對個人化醫療日益成長的需求,都在推動這些技術的應用。技術創新以及診斷開發公司與醫療服務提供者之間的夥伴關係,正在加強商業化進程。

複合年成長率最高的地區:

在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於醫療基礎設施的不斷改進、癌症發病率的上升以及對人工智慧技術投資的增加。中國、日本、印度、韓國和澳洲正在推動精準腫瘤學計畫和基因組檢測能力。分子診斷技術的普及、數位醫療措施的拓展以及臨床研究的不斷深入,正在加速這些技術的應用。政府對科技的投資以及醫療機構與生技公司之間的合作,也為該地區的成長提供了支持。

免費客製化服務:

所有購買此報告的客戶均可享受以下免費自訂選項之一:

  • 企業概況
    • 對其他市場參與者(最多 3 家公司)進行全面分析
    • 對主要公司進行SWOT分析(最多3家公司)
  • 區域分類
    • 根據客戶的興趣,我們將提供主要國家的市場估算和預測,以及複合年成長率(註:需經可行性確認)。
  • 競爭性標竿分析
    • 根據產品系列、企業發展和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章:研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章:競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球人工智慧驅動的精準腫瘤平台市場:依平台組件分類

  • 軟體
    • 獨立式精準腫瘤學軟體
    • 整合精準腫瘤學平台
  • 服務
    • 實施和整合服務
    • 臨床口譯及諮詢服務
    • 支援和維護服務

第6章:全球人工智慧驅動的精準腫瘤平台市場:以人工智慧技術分類

  • 機器學習和預測分析
  • 深度學習與神經網路
  • 自然語言處理
  • 生成式人工智慧和大規模語言模型
  • 多模態人工智慧和基礎模型
  • 基於知識圖譜的人工智慧
  • 可解釋和可理解的人工智慧
  • 其他人工智慧技術

第7章 全球人工智慧驅動的精準腫瘤學平台市場:依數據模態分類

  • 基因組和分子譜數據
  • 轉錄組和蛋白質組數據
  • 數位病理數據
  • 輻射和醫學影像數據
  • 電子健康記錄與臨床數據
  • 液態生物檢體和循環生物標記數據
  • 整合多體學和多模態數據
  • 其他資料模式

第8章 全球人工智慧驅動的精準腫瘤平台市場:依臨床應用分類

  • 分子生物標記的鑑定與解讀
  • 個人化治療方案
  • 預測標靶治療和免疫療法的反應
  • 癌症預後和風險分層
  • 預測治療抗藥性和疾病進展
  • 分子腫瘤學委員會決策支持
  • 臨床試驗配對和患者分層
  • 精準腫瘤學中的藥物發現與開發
  • 其他臨床用途

第9章 全球人工智慧驅動的精準腫瘤平台市場:依最終用戶分類

  • 醫院和醫療保健系統
  • 癌症中心和腫瘤診所
  • 分子診斷與基因組學檢測實驗室
  • 製藥和生物技術公司
  • 受託研究機構
  • 大學醫院和研究機構
  • 診斷和檢測機構
  • 其他最終用戶

第10章 由全球人工智慧驅動的精準腫瘤學平台市場:按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區(RoW)
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章:公司簡介

  • Tempus AI, Inc.
  • Caris Life Sciences, Inc.
  • SOPHiA GENETICS SA
  • Foundation Medicine, Inc.
  • Guardant Health, Inc.
  • BostonGene Corporation
  • GenomOncology LLC
  • Perthera, Inc.
  • Owkin, Inc.
  • PathAI, Inc.
  • Artera, Inc.
  • QIAGEN NV
  • Fabric Genomics, Inc.
  • Flatiron Health, Inc.
  • Syapse, Inc.
  • Roche Holding AG
  • Illumina, Inc.
  • Microsoft Corporation
Product Code: SMRC40927

According to Stratistics MRC, the Global AI-Driven Precision Oncology Platforms Market is estimated at $3.2 billion in 2026 and is expected to reach $13.4 billion by 2034, growing at a CAGR of 19.6% during the forecast period. AI-Driven Precision Oncology Platforms utilize machine learning, deep learning, natural language processing, and multimodal analytics to interpret molecular, clinical, and imaging data for personalized cancer management. Increasing cancer prevalence, growing adoption of genomic profiling, and demand for individualized treatment decisions are driving market growth. Technological advancements in generative AI, molecular diagnostics, and predictive analytics are improving clinical decision support. Expanding investment in precision medicine, oncology research, and digital healthcare infrastructure creates opportunities across hospitals, cancer centers, and pharmaceutical companies.

Market Dynamics:

Driver:

Increasing demand for personalized cancer treatment and AI-enabled clinical decision support

Increasing demand for personalized cancer treatment and AI-enabled clinical decision support is driving adoption of precision oncology platforms. Healthcare providers increasingly utilize genomic profiling, molecular diagnostics, and artificial intelligence to identify actionable biomarkers and support treatment selection. These platforms help clinicians interpret complex molecular information and evaluate targeted therapy options. Growing cancer prevalence, expanding precision medicine programs, and increasing availability of genomic data encourage adoption. Advances in machine learning and clinical data integration further strengthen market development.

Restraint:

High implementation costs and challenges in clinical data integration

High implementation costs and challenges in clinical data integration restrain adoption of AI-driven precision oncology platforms. Advanced solutions require sophisticated computational infrastructure, secure data environments, specialized personnel, and integration with existing hospital information systems. Differences in genomic data formats, electronic health records, and diagnostic workflows complicate interoperability. Limited reimbursement for certain AI-enabled services and uncertainty regarding clinical validation create additional barriers. Smaller healthcare organizations may face financial and technical challenges when implementing comprehensive platforms.

Opportunity:

Expansion of multimodal AI and integrated precision oncology applications

Expansion of multimodal AI and integrated precision oncology applications presents significant growth opportunities. Advanced platforms combine genomic profiles, digital pathology, medical imaging, and clinical records to generate comprehensive patient insights. Generative AI and foundation models offer opportunities to improve molecular interpretation, clinical trial matching, and treatment research. Pharmaceutical companies increasingly utilize AI-driven analytics for biomarker discovery and targeted therapy development. Growing investment in integrated healthcare data platforms and personalized oncology supports technological innovation.

Threat:

Algorithm reliability concerns and increasing patient data security risks

Algorithm reliability concerns and increasing patient data security risks pose significant challenges to AI-driven precision oncology platforms. Inaccurate molecular interpretations, biased training datasets, or poorly validated predictions may influence clinical decisions. Processing sensitive genomic and patient information creates cybersecurity and confidentiality concerns. Increasing regulatory scrutiny and requirements for explainable artificial intelligence raise development costs. Competition from established clinical decision support systems and conventional molecular interpretation workflows further challenges commercialization and widespread adoption.

Covid-19 Impact:

The COVID-19 pandemic accelerated healthcare digitalization and increased interest in remote clinical collaboration and AI-enabled diagnostic technologies. Oncology organizations explored digital platforms to support molecular tumor boards, clinical data interpretation, and treatment planning during disruptions to routine services. However, delayed cancer diagnoses, interrupted clinical trials, and constrained healthcare budgets affected implementation activities. Subsequent investment in digital healthcare infrastructure, precision medicine, and AI-supported oncology workflows continues to encourage market development.

The software segment is expected to be the largest during the forecast period

The software segment is expected to account for the largest market share during the forecast period due to increasing adoption of AI-enabled molecular interpretation, clinical decision support, and integrated oncology analytics platforms. Software solutions combine genomic data, electronic health records, and diagnostic information to support personalized treatment decisions. Growing investment in precision oncology programs, cloud-based healthcare platforms, and automated biomarker analysis encourages adoption. Advances in machine learning, workflow integration, and scalable clinical analytics strengthen segment growth.

The multimodal AI & foundation models segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the multimodal AI & foundation models segment is predicted to witness the highest growth rate due to increasing demand for integrated interpretation of diverse oncology datasets. These technologies combine genomic information, pathology images, radiology findings, and clinical records to support comprehensive cancer assessment. Advances in foundation models, generative AI, and computational infrastructure improve analytical capabilities. Growing investment in personalized treatment prediction, biomarker discovery, and oncology research is expected to accelerate adoption.

Region with largest share:

During the forecast period, North America is expected to hold the largest share due to advanced healthcare infrastructure, substantial investment in artificial intelligence, and extensive precision oncology activities. The United States leads regional development through biotechnology companies, cancer research centers, and healthcare organizations deploying AI-enabled molecular interpretation platforms. Increasing adoption of genomic testing, established clinical trial networks, and growing demand for personalized treatment encourage utilization. Technological innovation and partnerships between diagnostic developers and healthcare providers strengthen commercialization.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, increasing cancer prevalence, and growing investment in artificial intelligence technologies. China, Japan, India, South Korea, and Australia are advancing precision oncology programs and genomic testing capabilities. Improving access to molecular diagnostics, expanding digital healthcare initiatives, and increasing clinical research encourage adoption. Government technology investments and collaborations between healthcare institutions and biotechnology companies support regional growth.

Key players in the market

Some of the key players in the AI-Driven Precision Oncology Platforms Market include Tempus AI, Inc., Caris Life Sciences, Inc., SOPHiA GENETICS SA, Foundation Medicine, Inc., Guardant Health, Inc., BostonGene Corporation, GenomOncology LLC, Perthera, Inc., Owkin, Inc., PathAI, Inc., Artera, Inc., QIAGEN N.V., Fabric Genomics, Inc., Flatiron Health, Inc., Syapse, Inc., Roche Holding AG, Illumina, Inc., and Microsoft Corporation.

Key Developments:

In October 2026, Tempus AI, Inc. announced an expanded multi-year strategic collaboration with Bristol Myers Squibb to provide multimodal oncology data and access to its AI-powered Lens platform. The agreement supports oncology drug discovery, clinical research, and the development of advanced AI models for identifying therapeutic targets and improving precision oncology research.

In August 2026, Caris Life Sciences, Inc. announced the publication of research in npj Precision Oncology demonstrating an AI-driven approach to predicting first-line treatment benefit in pancreatic cancer. The study evaluated Caris AI Insights molecular signatures to support personalized therapy selection and improve clinical decision-making.

In June 2026, SOPHiA GENETICS SA announced a memorandum of understanding with Memorial Sloan Kettering Cancer Center to explore establishing a precision medicine joint venture. The collaboration aims to combine clinical diagnostic expertise with the SOPHiA DDM AI platform to develop and deploy advanced precision oncology solutions.

Platform Components Covered:

  • Software
  • Services

AI Technologies Covered:

  • Machine Learning & Predictive Analytics
  • Deep Learning & Neural Networks
  • Natural Language Processing
  • Generative AI & Large Language Models
  • Multimodal AI & Foundation Models
  • Knowledge Graph-Based AI
  • Explainable & Interpretable AI
  • Other AI Technologies

Data Modalities Covered:

  • Genomic & Molecular Profiling Data
  • Transcriptomic & Proteomic Data
  • Digital Pathology Data
  • Radiology & Medical Imaging Data
  • Electronic Health Records & Clinical Data
  • Liquid Biopsy & Circulating Biomarker Data
  • Integrated Multi-Omics & Multimodal Data
  • Other Data Modalities

Clinical Applications Covered:

  • Molecular Biomarker Identification & Interpretation
  • Personalized Treatment Selection
  • Targeted Therapy & Immunotherapy Response Prediction
  • Cancer Prognosis & Risk Stratification
  • Treatment Resistance & Disease Progression Prediction
  • Molecular Tumor Board Decision Support
  • Clinical Trial Matching & Patient Stratification
  • Precision Oncology Drug Discovery & Development
  • Other Clinical Applications

End Users Covered:

  • Hospitals & Health Systems
  • Cancer Centers & Oncology Clinics
  • Molecular Diagnostic & Genomics Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic Medical Centers & Research Institutions
  • Diagnostic & Reference Laboratories
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global AI-Driven Precision Oncology Platforms Market, By Platform Component

  • 5.1 Software
    • 5.1.1 Standalone Precision Oncology Software
    • 5.1.2 Integrated Precision Oncology Platforms
  • 5.2 Services
    • 5.2.1 Implementation & Integration Services
    • 5.2.2 Clinical Interpretation & Consulting Services
    • 5.2.3 Support & Maintenance Services

6 Global AI-Driven Precision Oncology Platforms Market, By AI Technology

  • 6.1 Machine Learning & Predictive Analytics
  • 6.2 Deep Learning & Neural Networks
  • 6.3 Natural Language Processing
  • 6.4 Generative AI & Large Language Models
  • 6.5 Multimodal AI & Foundation Models
  • 6.6 Knowledge Graph-Based AI
  • 6.7 Explainable & Interpretable AI
  • 6.8 Other AI Technologies

7 Global AI-Driven Precision Oncology Platforms Market, By Data Modality

  • 7.1 Genomic & Molecular Profiling Data
  • 7.2 Transcriptomic & Proteomic Data
  • 7.3 Digital Pathology Data
  • 7.4 Radiology & Medical Imaging Data
  • 7.5 Electronic Health Records & Clinical Data
  • 7.6 Liquid Biopsy & Circulating Biomarker Data
  • 7.7 Integrated Multi-Omics & Multimodal Data
  • 7.8 Other Data Modalities

8 Global AI-Driven Precision Oncology Platforms Market, By Clinical Application

  • 8.1 Molecular Biomarker Identification & Interpretation
  • 8.2 Personalized Treatment Selection
  • 8.3 Targeted Therapy & Immunotherapy Response Prediction
  • 8.4 Cancer Prognosis & Risk Stratification
  • 8.5 Treatment Resistance & Disease Progression Prediction
  • 8.6 Molecular Tumor Board Decision Support
  • 8.7 Clinical Trial Matching & Patient Stratification
  • 8.8 Precision Oncology Drug Discovery & Development
  • 8.9 Other Clinical Applications

9 Global AI-Driven Precision Oncology Platforms Market, By End User

  • 9.1 Hospitals & Health Systems
  • 9.2 Cancer Centers & Oncology Clinics
  • 9.3 Molecular Diagnostic & Genomics Laboratories
  • 9.4 Pharmaceutical & Biotechnology Companies
  • 9.5 Contract Research Organizations
  • 9.6 Academic Medical Centers & Research Institutions
  • 9.7 Diagnostic & Reference Laboratories
  • 9.8 Other End Users

10 Global AI-Driven Precision Oncology Platforms Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Tempus AI, Inc.
  • 13.2 Caris Life Sciences, Inc.
  • 13.3 SOPHiA GENETICS SA
  • 13.4 Foundation Medicine, Inc.
  • 13.5 Guardant Health, Inc.
  • 13.6 BostonGene Corporation
  • 13.7 GenomOncology LLC
  • 13.8 Perthera, Inc.
  • 13.9 Owkin, Inc.
  • 13.10 PathAI, Inc.
  • 13.11 Artera, Inc.
  • 13.12 QIAGEN N.V.
  • 13.13 Fabric Genomics, Inc.
  • 13.14 Flatiron Health, Inc.
  • 13.15 Syapse, Inc.
  • 13.16 Roche Holding AG
  • 13.17 Illumina, Inc.
  • 13.18 Microsoft Corporation

List of Tables

  • Table 1 Global AI-Driven Precision Oncology Platforms Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global AI-Driven Precision Oncology Platforms Market Outlook, By Platform Component (2023-2034) ($MN)
  • Table 3 Global AI-Driven Precision Oncology Platforms Market Outlook, By Software (2023-2034) ($MN)
  • Table 4 Global AI-Driven Precision Oncology Platforms Market Outlook, By Standalone Precision Oncology Software (2023-2034) ($MN)
  • Table 5 Global AI-Driven Precision Oncology Platforms Market Outlook, By Integrated Precision Oncology Platforms (2023-2034) ($MN)
  • Table 6 Global AI-Driven Precision Oncology Platforms Market Outlook, By Services (2023-2034) ($MN)
  • Table 7 Global AI-Driven Precision Oncology Platforms Market Outlook, By Implementation & Integration Services (2023-2034) ($MN)
  • Table 8 Global AI-Driven Precision Oncology Platforms Market Outlook, By Clinical Interpretation & Consulting Services (2023-2034) ($MN)
  • Table 9 Global AI-Driven Precision Oncology Platforms Market Outlook, By Support & Maintenance Services (2023-2034) ($MN)
  • Table 10 Global AI-Driven Precision Oncology Platforms Market Outlook, By AI Technology (2023-2034) ($MN)
  • Table 11 Global AI-Driven Precision Oncology Platforms Market Outlook, By Machine Learning & Predictive Analytics (2023-2034) ($MN)
  • Table 12 Global AI-Driven Precision Oncology Platforms Market Outlook, By Deep Learning & Neural Networks (2023-2034) ($MN)
  • Table 13 Global AI-Driven Precision Oncology Platforms Market Outlook, By Natural Language Processing (2023-2034) ($MN)
  • Table 14 Global AI-Driven Precision Oncology Platforms Market Outlook, By Generative AI & Large Language Models (2023-2034) ($MN)
  • Table 15 Global AI-Driven Precision Oncology Platforms Market Outlook, By Multimodal AI & Foundation Models (2023-2034) ($MN)
  • Table 16 Global AI-Driven Precision Oncology Platforms Market Outlook, By Knowledge Graph-Based AI (2023-2034) ($MN)
  • Table 17 Global AI-Driven Precision Oncology Platforms Market Outlook, By Explainable & Interpretable AI (2023-2034) ($MN)
  • Table 18 Global AI-Driven Precision Oncology Platforms Market Outlook, By Other AI Technologies (2023-2034) ($MN)
  • Table 19 Global AI-Driven Precision Oncology Platforms Market Outlook, By Data Modality (2023-2034) ($MN)
  • Table 20 Global AI-Driven Precision Oncology Platforms Market Outlook, By Genomic & Molecular Profiling Data (2023-2034) ($MN)
  • Table 21 Global AI-Driven Precision Oncology Platforms Market Outlook, By Transcriptomic & Proteomic Data (2023-2034) ($MN)
  • Table 22 Global AI-Driven Precision Oncology Platforms Market Outlook, By Digital Pathology Data (2023-2034) ($MN)
  • Table 23 Global AI-Driven Precision Oncology Platforms Market Outlook, By Radiology & Medical Imaging Data (2023-2034) ($MN)
  • Table 24 Global AI-Driven Precision Oncology Platforms Market Outlook, By Electronic Health Records & Clinical Data (2023-2034) ($MN)
  • Table 25 Global AI-Driven Precision Oncology Platforms Market Outlook, By Liquid Biopsy & Circulating Biomarker Data (2023-2034) ($MN)
  • Table 26 Global AI-Driven Precision Oncology Platforms Market Outlook, By Integrated Multi-Omics & Multimodal Data (2023-2034) ($MN)
  • Table 27 Global AI-Driven Precision Oncology Platforms Market Outlook, By Other Data Modalities (2023-2034) ($MN)
  • Table 28 Global AI-Driven Precision Oncology Platforms Market Outlook, By Clinical Application (2023-2034) ($MN)
  • Table 29 Global AI-Driven Precision Oncology Platforms Market Outlook, By Molecular Biomarker Identification & Interpretation (2023-2034) ($MN)
  • Table 30 Global AI-Driven Precision Oncology Platforms Market Outlook, By Personalized Treatment Selection (2023-2034) ($MN)
  • Table 31 Global AI-Driven Precision Oncology Platforms Market Outlook, By Targeted Therapy & Immunotherapy Response Prediction (2023-2034) ($MN)
  • Table 32 Global AI-Driven Precision Oncology Platforms Market Outlook, By Cancer Prognosis & Risk Stratification (2023-2034) ($MN)
  • Table 33 Global AI-Driven Precision Oncology Platforms Market Outlook, By Treatment Resistance & Disease Progression Prediction (2023-2034) ($MN)
  • Table 34 Global AI-Driven Precision Oncology Platforms Market Outlook, By Molecular Tumor Board Decision Support (2023-2034) ($MN)
  • Table 35 Global AI-Driven Precision Oncology Platforms Market Outlook, By Clinical Trial Matching & Patient Stratification (2023-2034) ($MN)
  • Table 36 Global AI-Driven Precision Oncology Platforms Market Outlook, By Precision Oncology Drug Discovery & Development (2023-2034) ($MN)
  • Table 37 Global AI-Driven Precision Oncology Platforms Market Outlook, By Other Clinical Applications (2023-2034) ($MN)
  • Table 38 Global AI-Driven Precision Oncology Platforms Market Outlook, By End User (2023-2034) ($MN)
  • Table 39 Global AI-Driven Precision Oncology Platforms Market Outlook, By Hospitals & Health Systems (2023-2034) ($MN)
  • Table 40 Global AI-Driven Precision Oncology Platforms Market Outlook, By Cancer Centers & Oncology Clinics (2023-2034) ($MN)
  • Table 41 Global AI-Driven Precision Oncology Platforms Market Outlook, By Molecular Diagnostic & Genomics Laboratories (2023-2034) ($MN)
  • Table 42 Global AI-Driven Precision Oncology Platforms Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 43 Global AI-Driven Precision Oncology Platforms Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 44 Global AI-Driven Precision Oncology Platforms Market Outlook, By Academic Medical Centers & Research Institutions (2023-2034) ($MN)
  • Table 45 Global AI-Driven Precision Oncology Platforms Market Outlook, By Diagnostic & Reference Laboratories (2023-2034) ($MN)
  • Table 46 Global AI-Driven Precision Oncology Platforms Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.